Clinical Trials Logo

Clinical Trial Summary

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05031832
Study type Observational
Source Chinese University of Hong Kong
Status Active, not recruiting
Start date June 1, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT03286218 - A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users Phase 1